<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373192">
  <stage>Registered</stage>
  <submitdate>23/06/2017</submitdate>
  <approvaldate>30/06/2017</approvaldate>
  <actrnumber>ACTRN12617000940370</actrnumber>
  <trial_identification>
    <studytitle>Effects of Inosine Supplements on Markers of Bone Health</studytitle>
    <scientifictitle>Effects of oral inosine supplements on bone turnover markers in healthy post-menopausal women</scientifictitle>
    <utrn>U111111982020</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post-menopausal bone health decline</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Inosine 500mg tablets (2 tablets in the  morning, 1 tablet in the evening) for 6 months. Adherence will be assessed by tablet counts of returned tablets. </interventions>
    <comparator>Placebo tablets (2 tablets in the  morning, 1 tablet in the evening) consisting of lactose, microcrystalline cellulose, and magnesium stearate.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1.	Change in P1NP using serum samples
</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2.	Change in ßCTx using serum samples
</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in serum urate</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in serum creatinine</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in systolic blood pressure</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in body mass index</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All adverse events (as defined by the FDA)</outcome>
      <timepoint>Over 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in grip strength using hand dynamometer</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in lipid profile (LDL, HDL, TG) using a serum assay</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fasting serum glucose</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in serum C-reactive protein</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fractional excretion of uric acid (FEUA) calculated from both serum and urine assays</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in diastolic blood pressure</outcome>
      <timepoint>Measured at 6 weeks, 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serious adverse events (as defined by the FDA)</outcome>
      <timepoint>Over 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>a.	Age &gt;55 years
b.	Post-menopausal 
c.	Female 
d.	eGFR &gt;60ml/min
e.	Serum urate &lt;0.42mmol/L
f.	Able to provide written informed consent and attend study visits
</inclusivecriteria>
    <inclusiveminage>56</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>a.	Bone mineral density T score &lt;-2.5 at the total hip, femoral neck or lumbar spine
b.	Previous fragility fracture of the hip or clinical spine fracture
c.	Current or past use of bisphosphonate therapy within 12 months, or any past zoledronate use
d.	Use of hormone replacement therapy within 12 months
e.	History of gout
f.	History of kidney stones
g.	History of diabetes mellitus
h.	Diuretic use
i.	Urine pH less than 5.0 (risk factor for uric acid urolithiasis)
j.	Current use of inosine as a nutritional supplement
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>17/01/2018</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <currentsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland</primarysponsorname>
    <primarysponsoraddress>85 Park Rd
Grafton
Auckland 1023
</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Auckland</fundingname>
      <fundingaddress>85 Park Rd
Grafton
Auckland 1023
</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A number of observational studies have indicated that urate has positive effects on bone. Inosine is a nutritional supplement (available as an over the counter supplement ) that increases serum urate levels. We plan a six month randomised, double-blind, placebo-controlled trial of 120 postmenopausal female participants. Participants will be randomised to one of two groups (60 participants per group): either placebo or inosine 1.5g daily (1g morning, 500mg evening). The coprimary endpoints will be change in markers of bone health (P1NP and ßCTX). Key secondary endpoints will be measures of kidney function, blood pressure and other features of metabolic syndrome.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
133 Molesworth Street
PO Box 5013
Wellington
6011</ethicaddress>
      <ethicapprovaldate>19/07/2017</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>23/06/2017</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth</name>
      <address>Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023
</address>
      <phone>+64 9 3737999</phone>
      <fax>+64 9 373 7677</fax>
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Jordyn Allan</name>
      <address>Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023</address>
      <phone>+64 9 9231747</phone>
      <fax>+64 9 373 7677</fax>
      <email>j.dekwant@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth</name>
      <address>Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023</address>
      <phone>+64 9 3737999</phone>
      <fax>+64 9 373 7677</fax>
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth</name>
      <address>Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023</address>
      <phone>+64 9 3737999</phone>
      <fax>+64 9 373 7677</fax>
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>